Top Nanotechnology Stocks To Follow Today – March 5th

OSI Systems, NVE, Virpax Pharmaceuticals, Biodexa Pharmaceuticals, and Clene are the five Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks are shares of companies that develop and commercialize products or technologies involving the manipulation of matter at the nanoscale, often at the atomic or molecular level. These stocks typically represent businesses operating across diverse sectors—such as healthcare, electronics, and materials science—where innovations in nanotechnology offer the potential for groundbreaking improvements and market disruption. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

Shares of OSI Systems stock traded down $10.46 during trading on Wednesday, reaching $181.22. The company’s stock had a trading volume of 329,007 shares, compared to its average volume of 217,359. The company has a quick ratio of 1.25, a current ratio of 1.88 and a debt-to-equity ratio of 0.56. The firm’s 50-day moving average is $187.44 and its two-hundred day moving average is $165.55. The company has a market cap of $3.04 billion, a price-to-earnings ratio of 23.30, a PEG ratio of 1.81 and a beta of 1.19. OSI Systems has a 52-week low of $126.57 and a 52-week high of $220.00.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

Shares of NASDAQ:NVEC traded up $1.51 during midday trading on Wednesday, reaching $65.63. The company’s stock had a trading volume of 10,134 shares, compared to its average volume of 20,607. NVE has a 12-month low of $63.89 and a 12-month high of $90.24. The firm has a market capitalization of $317.43 million, a P/E ratio of 21.07 and a beta of 1.11. The firm has a 50 day moving average of $76.20 and a 200-day moving average of $77.72.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

VRPX traded up $0.00 during trading on Wednesday, hitting $0.19. 940,204 shares of the company traded hands, compared to its average volume of 7,068,480. Virpax Pharmaceuticals has a 1 year low of $0.18 and a 1 year high of $5.48. The stock’s 50-day simple moving average is $0.31 and its two-hundred day simple moving average is $0.52.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Shares of BDRX traded up $0.12 during mid-day trading on Wednesday, hitting $2.92. The company’s stock had a trading volume of 20,387 shares, compared to its average volume of 241,081. Biodexa Pharmaceuticals has a 52-week low of $2.77 and a 52-week high of $74.00. The company has a 50-day moving average price of $4.18.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of CLNN stock traded up $0.19 on Wednesday, hitting $4.45. The company had a trading volume of 10,499 shares, compared to its average volume of 76,171. The company has a 50-day moving average price of $4.79 and a 200-day moving average price of $5.03. Clene has a twelve month low of $3.82 and a twelve month high of $10.40. The firm has a market cap of $37.03 million, a P/E ratio of -0.84 and a beta of 0.24.